Literature DB >> 14750765

Enophthalmos as initial manifestation of occult, mammogram-negative carcinoma of the breast.

Carol L Shields1, Gary A Stopyra, Brian P Marr, Mark L Moster, Jerry A Shields.   

Abstract

A patient with enophthalmos was found to have occult metastatic breast carcinoma to the orbit despite normal findings on breast examination and mammogram. Enophthalmos can be a sign of serious systemic disease and should be appropriately investigated. Despite radiologically interpreted normal orbital and breast imaging, the clinician should rule out underlying subclinical malignancy and consider orbital biopsy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14750765

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  5 in total

1.  Enophthalmos as a sign of metastatic breast carcinoma.

Authors:  Elena Novitskaya; Cornelius Rene
Journal:  CMAJ       Date:  2013-03-04       Impact factor: 8.262

Review 2.  Clinical Evaluation of Blepharoptosis: Distinguishing Age-Related Ptosis from Masquerade Conditions.

Authors:  Michelle W Latting; Alison B Huggins; Douglas P Marx; Joseph N Giacometti
Journal:  Semin Plast Surg       Date:  2017-02       Impact factor: 2.314

3.  Sclerosing Signet Ring Cell Carcinoma of the Lacrimal Gland: A Potentially New Primary Entity.

Authors:  Frederick A Jakobiec; Edith R Reshef; Lina Ma; Martin K Selig; Daniel R Lefebvre; Anna M Stagner
Journal:  Ocul Oncol Pathol       Date:  2020-02-07

4.  Sphenoid sinus expansion: a radiographic sign of intracranial hypotension and the sunken eyes, sagging brain syndrome (an American Ophthalmological Society thesis).

Authors:  Timothy J McCulley
Journal:  Trans Am Ophthalmol Soc       Date:  2013-09

5.  Orbital metastases in Italy.

Authors:  Patrizio Magliozzi; Diego Strianese; Paola Bonavolontà; Mariantonia Ferrara; Pasquale Ruggiero; Raffaella Carandente; Giulio Bonavolontà; Fausto Tranfa
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.